使用Lercanidipine可能之併發症：乳糜胸

Chylothorax as a Possible Complication of the Use of Lercanidipine

10.7023/TJFM.201209.0158

蘇子華(Tzu-Hua Su)；王志強(Chih-Ching Wang)；林任先(Jen-Hsien Lin)；蘇楠超(Nan-Chao Su)；項正川(Cheng-Chuan Hsiang)

lercanidipine ； calcium channel antagonist ； chylothorax ； chylous effusion

台灣家庭醫學雜誌

22卷3期（2012 / 09 / 01）

158 - 164

繁體中文

本文報告為86歲女性，因腹脹入院，大腸憩室炎經治療緩解後血壓仍偏高，增加lercanidipine每日10 mg，新生呼吸困難症狀，檢查證實為滲出性乳糜胸，排除常見原因與回顧用藥史，於lercanidipine使用上曾有引起乳糜腹的報告，推測應有相關，停藥後狀況明顯改善，且無復發。乳糜胸多為漏出性，滲出性乳糜胸則少見，治療上須矯正潛在病因才能緩解。

We report the case of an 86-year-old woman admitted due to sustained abdominal distension. Conservative treatment alleviated the abdominal symptoms, but we observed that her blood pressure remained high. A daily dose of lercanidipine 10 mg was added, but this was followed by the development of dyspnea. Testing confirmed a transudative chylothorax. We excluded common causes and reviewed her past medical history. The literature contains reports of lercanidipine-induced chyloperitoneum, so we considered a possible relationship between lercanidipine and chylothorax. After the administration of lercanidipine was discontinued, her condition improved and dyspnea did not recur. Chylous effusions are typically exudative, and transudative effusions are uncommon, but they can resolve if the etiology is discovered and corrected.

1. Heffner JE, Sahn SA, Hollingsworth H: Etiology, clinical presentation, and diagnosis of chylothorax. Uptodate 2012. http://www.uptodate.com/contents/etiology-clinical-presentation-and-diagnosis-of-chylothorax?source=search_result&search=chylothorax&selectedTitle=1%7E44#subscribeMessage. Accessed February 10, 2012.
2. Nyirady J, Schwartz RA, Nishikawa T, et al: Primary systemic amyloidosis clinical presentation. Medscape 2011. http://emedicine.medscape.com/article/1093258-clinical#a0217. Accessed February 20, 2012.
3. Holmes RO Jr, Baethge BA, Edison JD, et al: Amyloidosis. Medscape 2012. http://emedicine.medscape.com/article/335414-overview#aw2aab6b4. Accessed February 20, 2012.
4. Baranova, A.,Lal, P.,Birerdinc, A.,Younossi, Z.M.(2011).Non-invasive markers for hepatic fibrosis.BMC Gastroenterol,11,91-105.
5. Borghi, C.(2005).Lercanidipine in hypertension.Vasc Health Risk Manag,1,173-82.
6. Burns, J.P.,Truog, R.D.(2007).Futility: a concept in evolution.Chest,132,1987-93.
7. Cakmak, H.A.,Yenidünya, G.,Karada, B.,Ongen, Z.(2011).Development of chylothorax and chylous ascites in a patient with congestive heart failure.Turk Kardiyol Dern Ars,39,495-8.
8. Chang, Y.L.,Huang, C.E.,Chiu, C.T.,Wei, Y.F.,Lai, Y.F.(2009).Transudative chylothorax: two case reports and review of the literature.Thorac Med,24,193-8.
9. Hillerdal, G.(1997).Chylothorax and pseudochylothorax.Eur Respir J,10,1157-62.
10. Hsiao, P.J.,Lin, H.W.,Sung, C.C.,Wang, C.W.,Chu, P.,Lin, S.H.(2010).Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.Clin Nephrol,74,217-22.
11. Kodner, C.(2009).Nephrotic syndrome in adults: diagnosis and management.Am Fam Physician,80,1129-34.
12. Kuramoto, K.,Ichikawa, S.,Hirai, A.,Kanada, S.,Nakachi, T.,Ogihara, T.(2003).Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.Hypertens Res,26,201-8.
13. Maldonado, F.,Hawkins, F.J.,Daniels, C.E.,Doerr, C.H.,Decker, P.A.,Ryu, J.H.(2009).Pleural fluid characteristics of chylothorax.Mayo Clin Proc,84,129-33.
14. Pazos-López, P.,Peteiro-Vázquez, J.,Carcía-Campos, A.,García-Bueno, L.,de-Torres, J.P.,Castro-Beiras, A.(2011).The causes, consequences, and treatment of left or right heart failure.Vasc Health Risk Manag,7,237-54.
15. Quint, L.E.(2009).Thoracic complications and emergencies in oncologic patients.Cancer Imaging,9,75-82.
16. Rice, B.L.,Stoller, J.K.,Heresi, G.A.(2010).Transudative chylothorax associated with sclerosing mesenteritis.Respir Care,55,475-7.
17. Ryu, J.H.,Tomassetti, S.,Maldonado, F.(2011).Update on uncommon pleural effusions.Respirology,16,238-43.
18. Tanabe, M.,Iwata, H.,Kinoshita, M.,Sumiya, M.,Saima, S.(1999).Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus.Clin Nephrol,51,195-6.
19. Tsao, Y.T.,Chen, W.L.(2009).Calcium channel blocker-induced chylous ascites in peritoneal dialysis.Kidney Int,75,868.
20. Valentine, V.G.,Raffin, T.A.(1992).The management of chylothorax.Chest,102,586-91.
21. Yang, W.S.,Huang, J.W.,Chen, H.W.,Tsai, T.J.,Wu, K.D.(2008).Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.Perit Dial Int,28,632-6.